| Literature DB >> 33193283 |
Joon Soo An1, Seong-Heon Hong1, Elisabeth Somers2, Jayho Lee3, Byung-Yong Kim4, Donghee Woo1, Suk Won Kim1, Hee-Jeon Hong2, Shin-Il Jo5, Jongheon Shin1, Ki-Bong Oh3, Dong-Chan Oh1.
Abstract
Symbiotic microorganisms associated with insects can produce a wide array of metabolic products, which provide an opportunity for the discovery of useful natural products. Selective isolation of bacterial strains associated with the dung beetle, Onthophagus lenzii, identified two strains, of which the antibiotic-producing Brevibacillus sp. PTH23 inhibited the growth of Bacillus sp. CCARM 9248, which is most closely related to the well-known entomopathogen, Bacillus thuringiensis. A comprehensive chemical investigation based on antibiotic activity discovered two new antibiotics, named lenzimycins A and B (1-2), which inhibited growth of Bacillus sp. CCARM 9248. The 1H and 13C NMR, MS, MS/MS, and IR analyses elucidated the structures of 1 and 2, which comprised a novel combination of fatty acid (12-methyltetradecanoic acid), glycerol, sulfate, and N-methyl ethanolamine. Furthermore, the acid hydrolysis of 1 revealed the absolute configuration of 12-methyltetradecanoic acid as 12S by comparing its optical rotation value with authentic (R)- and (S)-12-methyltetradecanoic acid. In addition to inhibition of Bacillus sp. CCARM 9248, lenzimycins A and B were found to inhibit the growth of some human pathogenic bacteria, including Enterococcus faecium and certain strains of Enterococcus faecalis. Furthermore, the present study elucidated that lenzimycins A and B activated a reporter system designed to detect the bacterial cell envelope stress, thereby indicating an activity against the integrity of the bacterial cell wall.Entities:
Keywords: Bacillus; Brevibacillus; antibiotic; dung beetle; lenzimycin; natural product
Year: 2020 PMID: 33193283 PMCID: PMC7661691 DOI: 10.3389/fmicb.2020.599911
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1A specimen Onthophagus lenzii.
FIGURE 2Structures of lenzimycins A and B (1-2).
1H and 13C NMR spectral data for lenzimycins A and B (1-2) in CDCl3.
| 1 | 173.8 | C | 173.3 | C | ||||
| 2 | 34.1 | CH2 | 2.30 | t (7.7) | 34.3 | CH2 | 2.30 | t (7.0) |
| 3 | 24.9 | CH2 | 1.60 | m | 24.9 | CH2 | 1.60 | m |
| 4–10 | 30.0-27.1 | CH2 | 1.31-1.23 | m | 30.0-27.1 | CH2 | 1.31-1.23 | m |
| 11 | 36.6 | CH2 | 1.27, 1.07 | m | 36.6 | CH2 | 1.27, 1.07 | m |
| 12 | 34.4 | CH | 1.28 | m | 34.4 | CH | 1.28 | m |
| 12-Me | 19.2 | CH3 | 0.83 | t (6.5) | 19.2 | CH3 | 0.84 | t (6.5) |
| 13 | 29.5 | CH2 | 1.25, 1.12 | m | 29.5 | CH2 | 1.25, 1.12 | m |
| 14 | 11.4 | CH3 | 0.84 | t (7.2) | 11.4 | CH3 | 0.85 | t (7.2) |
| 1′ | 64.5 | CH2 | 4.11 | m | 59.8 | CH2 | 3.73 | d (5.3) |
| 2′ | 69.1 | CH | 3.98 | m | 72.5 | CH | 4.97 | m |
| 3′ | 68.1 | CH2 | 4.00, 3.90 | m | 63.4 | CH2 | 4.08 | m |
| 1″″ | 61.6 | CH2 | 4.19 | m | 61.2 | CH2 | 4.20 | m |
| 2″ | 49.7 | CH2 | 3.15 | m | 49.9 | CH2 | 3.14 | m |
| 2″-NH | 9.64 | br s | 9.73 | br s | ||||
| 2″-N-Me | 33.6 | CH3 | 2.70 | s | 33.7 | CH3 | 2.71 | s |
Antibacterial activity of lenzimycins A and B (1-2) against a panel of bacterial species.
| 1 | CCARM 9248 | 64 | 8 | 16 | 0.12 | ||
| 2 | CCARM 0002 | 128 | 128 | 8 | 1 | ||
| 3 | CCARM 5171 | susceptibl | >128 | >128 | 2 | 1 | |
| 4 | CCARM 5025 | VRE | >128 | >128 | 2 | 2 | |
| 5 | CCARM 5024 | VRE | 0.5 | 1 | 32 | 4 | |
| 6 | CCARM 0205 | susceptible | 32 | 64 | 2 | 1 | |
| 7 | CCARM 3855 | susceptible | >128 | >128 | 0.25 | 1 | |
| 8 | CCARM 3089 | MDR | >128 | >128 | 64 | 128 | |
| 9 | CCARM 0230 | >128 | >128 | 2 | 0.03 | ||
| 10 | CCARM 0237 | >128 | >128 | 8 | 0.5 | ||
| 11 | CCARM 0235 | >128 | >128 | 4 | 0.06 | ||
| 12 | CCARM 0219 | >128 | >128 | >128 | 1 | ||
| 13 | CCARM 0223 | >128 | >128 | >128 | 0.5 | ||
| 14 | CCARM 0225 | >128 | >128 | 0.5 | 0.25 | ||
| 15 | CCARM 0240 | >128 | >128 | 1 | 0.06 | ||
| 16 | CCARM 0252 | >128 | >128 | >128 | 0.06 | ||
| 17 | CCARM 0253 | >128 | >128 | 1 | 0.03 | ||
| 18 | CCARM 0248 | >128 | >128 | >128 | 0.03 | ||
| 19 | CCARM 0249 | >128 | >128 | 2 | 0.06 | ||
| 20 | ATCC 25922 | QC | >128 | >128 | 4 | 0.06 | |
| 21 | ATCC 29212 | QC | >128 | >128 | 0.5 | 2 ∼ 8 | |
| 22 | ATCC 19434 | QC | 16 | 8 | 0.5 | – | |
| 23 | ATCC 27853 | QC | >128 | >128 | >128 | 1 ∼ 4 | |
| 24 | ATCC 29213 | QC | >128 | >128 | 0.13 | 0.5 ∼ 2 | |
| 25 | ATCC 14028 | QC | 128 | 128 | 0.13 | – | |
| 26 | ATCC 10031 | QC | >128 | >128 | 32 | – | |
FIGURE 3Detailed analysis of planar structures of lenzimycins. (A) Key 1H-1H COSY and HMBC correlations of lenzimycins A and B (1-2). (B) ESI-HR-MS/MS fragmentation of lenzimycin A (1). (C) Rearrangement between lenzimycins A and B (1-2).
Antibacterial activity of lenzimycins A and B (1-2) against additional clinical isolates of Enterococci.
| Parent strain, vancomycin sensitive | 3.1 | 1.6 | 25 | 3.1 | 25 | |
| JH2-2::Tn1546, inducible resistance, VanA-type VREf | 4.2 | 10.4 | >100 | >100 | 83 | |
| JH2-2::Tn1549, inducible resistance, VanB-type VREf | 6.3 | 6.3 | >100 | 50 | 83 | |
| point mutation in | 4.2 | 6.3 | 100 | 83 | 83 | |